Abstract
Most smartphones and wearables are nowadays equipped with location sensing (using Global Positioning System and mobile network information) that enable continuous location tracking of their users. Several studies have reported that the amount of time an individual experiencing symptoms of Major Depressive Disorder (MDD) spends at home a day (i.e., home stay), as well as various mobility related metrics, are associated with symptom severity in MDD. Due to the use of small and homogeneous cohorts of participants, it is uncertain whether the findings reported in those studies generalize to a broader population of individuals with the MDD symptoms. In the present study, we examined the relationship between overall severity of the depressive symptoms, as assessed by the eight-item Patient Health Questionnaire (PHQ-8), and median daily home stay over the two weeks preceding the completion of a questionnaire in individuals with MDD. We used questionnaire and geolocation data of 164 participants collected in the observational Remote Assessment of Disease and Relapse – Major Depressive Disorder (RADAR-MDD) study. Participant age and severity of the MDD symptoms were found to be significantly related to home stay, with older and more severely affected individuals spending more time at home. The association between home stay and symptom severity appeared to be stronger on weekdays than on weekends. Furthermore, we found a significant modulation of home stay by occupational status, with employment reducing home stay. Our findings suggest that home stay is associated with symptom severity in MDD and demonstrate the importance of accounting for confounding factors in future MDD studies.
Competing Interest Statement
Dzmitry A. Kaliukhovich and Nikolay V. Manyakov are employees of Janssen Pharmaceutica NV and may hold company equity. Srinivasan Vairavan and Vaibhav A. Narayan are employees of Janssen Research & Development, LLC and may hold company equity. Peter Annas is an employee of Lundbeck A/S and may hold company equity. All authors declare that they have no competing financial, professional, or personal interests that might have influenced the performance or presentation of the work described in the manuscript.
Funding Statement
The RADAR-CNS project has received funding from the Innovative Medicines Initiative (IMI) 2 Joint Undertaking under grant agreement no. 115902. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA (www.imi.europa.eu). This communication reflects the views of the RADAR – CNS consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. Participant recruitment in Amsterdam was partially accomplished through Hersenonderzoek.nl, a Dutch online registry that facilitates participant recruitment for neuroscience studies (www.hersenonderzoek.nl). Hersenonderzoek.nl is funded by ZonMw – Memorabel (project no. 73305095003), a project in the context of the Dutch Deltaplan Dementie, Gieskes – Strijbis Foundation, the Alzheimer's Society in the Netherlands and Brain Foundation Netherlands. Participants from the CIBER group were recruited from the following Heath Care centers: Parc Sanitari Sant Joan de Deu Network services, Institut Catala de la Salut- IDIAP Jordi Gol, (Catalonia) Institut Pere Mata Hospital Clinico San Carlos, Madrid, Spain. We also acknowledge the great contribution of all participants with MDD across sites. This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
RADAR - MDD is conducted per the Declaration of Helsinki and Good Clinical Practice, adhering to principles outlined in the NHS Research Governance Framework for Health and Social Care (2nd edition). Ethical approval has been obtained in London from the Camberwell St Giles Research Ethics Committee (REC reference: 17/LO/1154), in London from the CEIC Fundacio Sant Joan de Deu (CI: PIC - 128 - 17) and in The Netherlands from the Medische Ethische Toetsingscommissie VUms (METc VUmc registratienummer: 2018.012 - NL63557.029.17). All staff working on the study have received training in study conduct, informed consent and risk assessment. RMT data are pseudonymised and stored in a research database in accordance with the General Data Protection Regulation. The informed consent process ensures that participants understand the nature of the study, and the data being collected. Interested individuals are sent the study materials, including information sheet and consent form to review. If, after reading, they wish to participate, they are invited to an enrolment session which involves the collection of written consent before the administration of any study procedures. They understand that their privacy is protected, that they can withdraw at any time without giving a reason, and request to have all data collected from them deleted. Participants may not necessarily be in contact with healthcare services during the study, but for those that are, their relationships with their care teams is not be impacted by participation or withdrawal from the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data can be requested from the RADAR-MDD consortium
